ArticleBMC medicine2015
Lifetime risk of being diagnosed with, or dying from, prostate cancer by major ethnic group in England 2008-2010.
Article in BMC medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Inclusivity in prostate cancer and exercise research: a systematic review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Pooled it
- Androgen receptor binding sites enabling genetic prediction of mortality due to prostate cancer in cancer-free subjects.Nature communications · 2023Pooled it
- Pooled it
- Utilisation of the STEAP protein family in a diagnostic setting may provide a more comprehensive prognosis of prostate cancer.PloS one · 2019Trial
- Integrated multi-omics profiling uncovers the epigenetic, transcriptional, and metabolic landscape of prostate cancer progression.BMC cancer · 2026Article
- Physical Activity, Trust, and Research Participation Among Men From Minority Ethnic Backgrounds Living With Prostate Cancer: A Qualitative Study.Psycho-oncology · 2026Article
- Modulators of epithelial-mesenchymal transitions in prostate cancer: potential for novel therapeutics development.Frontiers in pharmacology · 2026Article
- Article
- Rising metastatic prostate cancer rates but narrowing racial gap.BMC medicine · 2025Article
- Developing a Patient Experience Questionnaire for the Man Van Mobile Clinical Unit.Health expectations : an international journal of public participation in health care and health policy · 2025Article
- Barriers and facilitators to accessing healthcare for early diagnosis of prostate cancer for black men-a qualitative exploration in North-East England and Scotland.BMC public health · 2025Article
- Article
- Racial disparities in prostate cancer in the UK and the USA: similarities, differences and steps forwards.Nature reviews. Urology · 2025Review
- Epigenetic and biogenetic regulation by polyphenols in prostate cancer in the context of 3P medicine.The EPMA journal · 2025Review
- Using real world data to bridge the evidence gap left by prostate cancer screening trials.ESMO real world data and digital oncology · 2024Article
- Screening guidelines for individuals at increased risk for prostate cancer.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2024Review
- Article
- Optimising the use of the prostate- specific antigen blood test in asymptomatic men for early prostate cancer detection in primary care: report from a UK clinical consensus.The British journal of general practice : the journal of the Royal College of General Practitioners · 2024Article
- Towards a 'clicked' PSMA targeting gene delivery bioconjugate-polyplex for prostate cancer.RSC advances · 2024Article
- Prostate Cancer Among Black Men in Canada.JAMA network open · 2024Observational
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn the UK, a man's lifetime risk of being diagnosed with prostate cancer is 1 in 8. We calculated both the lifetime risk of being diagnosed with and dying from prostate cancer by major ethnic group.
methodsPublic Health England provided prostate cancer incidence and mortality data for England (2008-2010) by major ethnic group. Ethnicity and mortality data were incomplete, requiring various assumptions and adjustments before lifetime risk was calculated using DevCan (percent, range).
resultsThe lifetime risk of being diagnosed with prostate cancer is approximately 1 in 8 (13.3 %, 13.2-15.0 %) for White men, 1 in 4 (29.3 %, 23.5-37.2 %) for Black men, and 1 in 13 (7.9 %, 6.3-10.5 %) for Asian men, whereas that of dying from prostate cancer is approximately 1 in 24 (4.2 %, 4.2-4.7 %) for White men, 1 in 12 (8.7 %, 7.6-10.6 %) for Black men, and 1 in 44 (2.3 %, 1.9-3.0 %) for Asian men.
conclusionsIn England, Black men are at twice the risk of being diagnosed with, and dying from, prostate cancer compared to White men. This is an important message to communicate to Black men. White, Black, and Asian men with a prostate cancer diagnosis are all as likely to die from the disease, independent of their ethnicity. Nonetheless, proportionally more Black men are dying from prostate cancer in England.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.